ArticleBMJ open2020

Protocol of a prospective, multicentre phase I study to evaluate the safety, tolerability and preliminary efficacy of the bispecific PSMAxCD3 antibody CC-1 in patients with castration-resistant prostate carcinoma.

Jonas S Heitmann et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.